Buscar
Mostrando ítems 11-20 de 748
C-Reactive protein and insulin growth factor 1 serum levels during the menstrual cycle in adolescents with Type 1 diabetes
(Blackwell Publishing Ltd, 2016)
© 2016 Diabetes UK.Aims: To evaluate C-reactive protein, insulin growth factor 1 and lipid levels during the follicular and luteal phases in adolescents with Type 1 diabetes. Methods: Adolescents with Type 1 diabetes (N = ...
Metabolic profile in sons of women with polycystic ovary syndrome
(Endocrine Society, 2008)
Context: Polycystic ovary syndrome (PCOS) is a common endocrine-metabolic disorder with strong familial aggregation. It has been demonstrated that parents and brothers of PCOS women exhibit insulin resistance and related ...
Clinical review: Hyperandrogenism and polycystic ovary syndrome in women with type 1 diabetes mellitus
(Endocrine Society, 2007)
Context: At present, women with type 1 diabetes (DM1) are being treated with supraphysiological doses of exogenous insulin with the aim of providing a strict metabolic control, thereby avoiding the long-term complications ...
Subjects with impaired fasting glucose: Evolution in a period of 6 years
(Hindawi Publishing Corporation, 2014)
© 2014 E. Leiva et al. Aim. To study the evolution of impaired fasting glucose (IFG), considering glucose and HbA1c levels and risk factors associated, in a period of 6 years. Methods. We studied 94 subjects with impaired ...
Thyroxine (T4) and triiodothyronine (T3): Effects of iodine on the serum concentrations and disposal rates in subjects from an endemic goiter area
(1974)
In iodine-deficient subjects the T3 and T4 peripheral metabolism was studied. A diminished disposal rate of T4 and an increase in T3 were found. Serum concentrations and disposal rates of both hormones were determined ...
Pulsatile Luteinizing Hormone Secretion in Women with Polycystic Ovary Syndrome under Clomiphene Citrate. Differences between Responders and Nonresponders
(1990)
Although administration of Clomiphene Citrate (CC) is an effective therapy for ovulation induction in PCO patients, 15 to 20% of PCO patients do not ovulate following CC treatment. The aim of this study was to compare the ...
Late luteal phase administration of RU486 for three successive cycles does not disrupt bleeding patterns or ovulation
(1987)
RU486, a 19-nor steroid, binds with high affinity to the receptors for progesterone and glucocorticoids, blocking the actions of these hormones on their target tissues. We conducted studies to determine whether RU486 ...